Osborne Clarke has advised Creo Medical Group on a successful fundraising to raise £52m by way of a placing and open offer.
Creo intends to use the net proceeds from the fundraising for working capital to provide a strong balance sheet to continue its commercialisation of the CROMA Advanced Energy Platform and associated devices, as well as to provide funds for strategic developments.
Creo Medical Group is a medical device company focused on the emerging field of surgical endoscopy, quoted on the AIM market of the London Stock Exchange.
The Osborne Clarke team that advised on the transaction was led by Corporate Partner Mark Wesker (Picture) and Senior Associate Ashley Morris.
Law Firms: Osborne Clarke;
Clients: Creo Medical Group;